At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 219 enrolled
Drug / intervention
Fostamatinib disodium (R935788) +1 moredrug
Likely dose
Fostamatinib disodium (R935788) 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic
In Brief
A Phase 2 clinical trial evaluating Fostamatinib disodium (R935788) and Placebo for Rheumatoid Arthritis. Completed, enrolled 219 participants across 44 sites in 7 countries.
Detailed Summary
The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) Inhibitor, R935788 (R788) at a dose of 100 mg, tablet, orally, twice-a-day is effective in the treatment of Rheumatoid Arthritis in patients who have 'failed' a biologic therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBelgium, Colombia, France, Germany, Italy, Peru, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartMay 2008
Primary CompletionJun 2009
TodayJul 2026
First PostedApr 24, 2008
Enrollment StartMay 1, 2008
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.2 years ago
Interventions
Fostamatinib disodium (R935788)drug
R935788 100 mg tablet, orally, twice-a-day
Placebodrug
Placebo, orally, twice-a-day